ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1670

Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset

Fatima Barbar-Smiley1, Danlei Zhou2, Joanne Drew2, Bi Zhou2, Cagri Yildirim-Toruner2, Vidya Sivaraman3, Wael Jarjour4, Stacy Ardoin2 and Chack-Yung Yu5, 1Nationwide Children's Hospital/The Ohio State University, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital, Bexley, OH, 4The Ohio State University, Columbus, OH, 5Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH

Meeting: ACR Convergence 2020

Keywords: complement, Disease Activity, Gene Expression, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Hypocomplementemia is a marked feature of systemic lupus erythematosus (SLE), which may be a result of consumption initiated by immune complexes between self-nuclear antigens and autoantibodies. Lower copy number of C4 genes is cited as a risk factor for SLE. Located in the MHC class III region on chromosome 6, there are two versions of C4 genes: the long gene and the short gene. This variation is triggered by the integration of an endogenous retrovirus HERV-K(C4) into intron 9 of the long genes. The role that long and short C4 genes plays in SLE pathogenesis remains unclear. This is especially important for childhood onset SLE (cSLE), as childhood-onset SLE conveys worse disease outcomes when compared to adult onset SLE. To help further understand the role of C4 genetic variants in the immune pathogenesis of cSLE, we performed a cross-sectional case-control study of 37 patients with cSLE (mean age: 19.08±3.22 yo; 81.1% female) and 40 healthy children (mean age: 19.30±3.75 yo; 75% female).

Methods: EDTA-Blood samples were obtained after informed consent and assent. Blood differentials for all samples were measured using a Sysmex automated hematology analyzer. Plasma protein concentrations of complement C4 and C3 were assayed by radial immunodiffusions (Binding Sites, UK); polymorphisms of C4 proteins for C4A and C4B allotypes were determined by immunofixation; gene copy numbers of total C4, C4A, C4B, long C4 genes and short C4 genes were elucidated by multiple genomic Southern blot analyses.  Binary analyses of categorical data were performed by Chi2 analyses. Continuous data between groups were compared by Student’s t-test or analyzed by linear regression.  Because of small sample size, our pilot analysis is focused on Caucasian patients (N=21) and Caucasian healthy controls (N=31).

Results: We observed significantly lower lymphocyte counts (1.81±0.87 x103 /ml vs 2.51±0.75x x103 /ml, p=0.0004) and complement C4 plasma protein concentrations (19.8±7.7 mg/dL vs 25.4±7.4 mg/dL; p=0.002), plus lower C4 protein yield per copy of C4 genes (5.63±1.84 mg/dL vs 6.59±1.79 mg/dL; p=0.025) in cSLE patients than in controls. The mean protein levels for complement C3 were similar between patients and controls (126.4 vs 133.0, p=0.25). Genetically, the copy number of long C4 genes was significantly lower among cSLE patients (2.30±1.081) than controls (2.903±0.944; p=0.04).  Subjects with only one or two copies of long C4 genes had an odds ratio of 6.36 (95% CI: 1.83-22.1) on genetic risk of cSLE (p=0.0023). The age of onset or diagnosis among patients with cSLE was inversely correlated with copy number of long C4 genes (R2=0.38, p=0.0036), a phenomenon that remains true when patients with other racial groups were included in the analyses (R2=0.23, p=0.0032). 

Conclusion: Diversities of complement C4 genes and variation in levels of plasma C4 proteins are both a cause and an effect of cSLE.  Intriguingly, the inverse relation of copy number long C4 genes with age of onset was an unexpected finding and its clinical implications, though, is yet to be explored. A larger study sample will help us better understand the potential role that long C4 gene plays in SLE pathogenesis and its implications on lupus disease activity or clinical outcomes.


Disclosure: F. Barbar-Smiley, None; D. Zhou, Nationwide children's hospital, 1, 2, 3, 4, 5, 6, 7, 8, 9; J. Drew, None; B. Zhou, None; C. Yildirim-Toruner, None; V. Sivaraman, None; W. Jarjour, None; S. Ardoin, None; C. Yu, None.

To cite this abstract in AMA style:

Barbar-Smiley F, Zhou D, Drew J, Zhou B, Yildirim-Toruner C, Sivaraman V, Jarjour W, Ardoin S, Yu C. Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/low-copy-number-of-long-c4-genes-is-a-genetic-risk-factor-for-childhood-onset-sle-csle-but-is-associated-with-higher-age-of-disease-onset/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-copy-number-of-long-c4-genes-is-a-genetic-risk-factor-for-childhood-onset-sle-csle-but-is-associated-with-higher-age-of-disease-onset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology